Olympus Supports CMS Coverage Decision for Lung Cancer Screening
Retrieved on:
Tuesday, May 24, 2022
People, Laparoscopy, Disease, Method, Lung cancer, American College of Chest Physicians, PJ, Olympus Corporation, Center, Lymph, Lammers, Physician, Rose M. Likins, Medicaid, Lung, American Lung Association, Quality of life, Ultrasound, NSCLC, Research, Medicare, Neoplasm, Large-cell lung carcinoma, PMID, Centers for Medicare & Medicaid Services, CMS, American College, Survival, CM, Multimedia, Smoker, Mediastinoscopy, Endoscopy, EBUS, Awareness, Kątki, Mediastinum, United States Preventive Services Task Force, Olympus, Patient, User experience, Survival rate, Decision-making, USPSTF, Lung cancer staging, Veni, vidi, vici, Prognosis, Diagnosis, Health insurance, Medical imaging, Medical device, Mobile phone, Silviculture, Medicine
CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.
Key Points:
- CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.
- Earlier screening and detection may save the lives of those diagnosed with non-small cell lung cancer," said Paul Skodny, Executive Director of Global Health Economics and Market Access at Olympus Corporation of the Americas.
- "Still, there is much work to be done to align CMS coverage through Medicare and Medicaid with lung cancer screening guidance so that the barriers to screening are eliminated."
- Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.